Biotech Firm to Test AIDS Vaccine
June 12, 2003
Targeted Genetics Corp., an unprofitable developer of gene-therapy drugs, said it will begin human tests of an AIDS vaccine this year after seeing positive results in animal studies. The vaccine, tgAACO9, prompted an immune response in rabbits, the company said in a statement. Safety testing in humans will begin in the second half of 2003, according to the Seattle-based company. Earlier this year, Targeted Genetics reduced its work force and cut some research programs to conserve cash for developing its AIDS vaccine and cystic fibrosis and arthritis therapies.
06.07.03; Bloomberg News
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.